UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) but lowers the price target from $89 to $85.

May 08, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS maintains a Buy rating on Apellis Pharmaceuticals but lowers the price target from $89 to $85.
While the reduction in price target from $89 to $85 by UBS could be seen as a negative adjustment, the maintenance of a Buy rating by analyst Eliana Merle suggests a continued positive outlook on the company's fundamentals. This mixed signal might lead to a neutral short-term impact on the stock price, as the market digests both the endorsement of the company's potential and the slight tempering of expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100